The emergence of large-scale multi-omics data warrants method development for data integration.
Introduction

42
A central goal of cancer genomics is to identify key genetic and epigenetic alterations that promote 43 initiation and/or progression of cancer. These alterations can manifest themselves across multiple 44 biological levels -DNA, RNA, proteinand can be correspondingly quantified by multiple high-45 throughput profiling technologies.
46
Large-scale cancer genomics data compendia such as The Cancer Genome Atlas (TCGA) have generated comprehensive multi-omics datasets for tens of thousands of patients across ~30 types of cancer (Cancer 48 Genome Research Network, 2013) . The availability of such large-scale datasets provides an opportunity 49 to develop methods that integrate data from multiple types of profiling platforms, supporting the 50 discovery of novel candidate driver genes and eventually diagnostic and prognostic biomarkers and 51 therapeutic targets.
52
Past research using integrative approaches have shown success in discovering novel cancer drivers 53 (Akavia et al. 2010; Xie et al. 2012) . However, many existing methods often rely on ad-hoc, albeit 54 sophisticated, analysis methods and scripts not accessible to analysts other than those responsible for their 4 address this problem is to prune the set of candidate drivers based on their association with paired omics 66 data, such as gene expression profiles. For example, one can prioritize genes found in frequent SCNA 67 peaks whose gene expression changes are associated with corresponding copy number changes (Monti et 68 al. 2012 al. , Lai et al. 2017 . Even after this pruning step, the set of remaining candidate drivers might still 69 yield too many testable hypotheses for use in functional validation studies. More importantly, association 70 between SCNA and gene expression alone may not be the best metric for ranking potential cancer drivers.
71
To address this problem, we developed a methodology that identifies SCNA-(or other alteration-72 )associated genes and performs prediction of cis gene drivers prioritized by their capability of 73 transactivating downstream gene expression (trans effects), by leveraging the trans-gene signature (gene 74 sets outside the SCNA of interest) whose expression is also associated with a given SCNA event of 75 interest. The approach is predicated on the hypothesis that SCNA-related drivers of tumorigenesis will 76 mediate a larger proportion of the downstream effect observable by trans gene expression than non-77 drivers. Using this heuristic, and based on the Sobel test of mediation (Sobel 1982) , we identify putative 78 SCNA-associated cancer drivers as the cis gene mediating the most trans gene expression, although the 79 method allows users to customize the set of trans genes considered for the ranking of putative cis gene 80 drivers.
81
We developed a corresponding software tool, integration of Epi-DNA and Gene Expression (iEDGE) , 82 available at https://github.com/montilab/iEDGE, for the prediction of (epi-)DNA-associated cancer 83 drivers. Some of iEDGE's methodological components were previously applied to the cis/trans analysis 84 of diffuse large B cell lymphoma multi-omics datasets, and have shown success in uncovering SCNA-85 associated cis driver genes (Chapuy et al. 2018 , Monti et al. 2012 . Here, we present an expanded and 86 optimized method crucially incorporating the mediation step, and we present the results of its application 87 to the prediction of SCNA-associated cancer drivers across 19 cancer types using data from TCGA, with 88 a particular focus on analysis of TCGA breast cancer. Our list of candidate drivers is highly enriched for 5 known oncogenes and tumor suppressors and additionally implicates many suspected drivers as well as 90 novel candidate genes with potential prognostic or therapeutic importance in cancer. deletions. Next, we identified sets of cis and trans genes with significant differential expression with 100 respect to each SCNA, and performed, pathway enrichments of cis and trans gene sets ( Figure 1A ).
Results
92
101
A list of cis genes whose expression is significantly associated with each SCNA is summarized in 102 Supplemental Table S1 (Fold change > 1.2, one-directional FDR <0.25). This list comprises an average of 103 20 genes (and a median of 8 genes) per SCNA, with 1330 genes in total (269 in amplifications, 1061 in 104 deletions) out of the original 2003 genes across all SCNAs identified using GISTIC2.0, a number clearly 105 still too large for meaningful consideration for functional validation.
106
Similarly, a list of significantly differentially expressed trans genes is summarized in Supplemental Table   107 S2 (Fold change > 1.5, bi-directional FDR < 0.1). This list contains an average of 865 (a median of 598) 108 significant trans genes per SCNA.
109
Pathway enrichment analyses of the union of cis and trans genesets yielded interesting and potentially 110 biological meaningful patterns ( Figure 2 ). In particular, several pathways were enriched across most 7 since co-occurring SCNAs will tend to have overlapping trans signatures, hence common pathway 116 enrichments. To elucidate breast cancer subtype specific pathway enrichments, we categorized each 117 SCNA by their enrichment in each of four major breast cancer types: Luminal A, Luminal B, Her2, Basal.
118
In addition, for each pathway, we tested if the enrichment across SCNAs tended to occur in subtype-119 specific SCNAs compared to non-subtype-specific SCNAs (Figure 2 ). Several significant pathways were 120 found to be occurring more frequently in Basal-specific SCNAs, including Figure 1B ). For each SCNA in the TCGA breast cancer dataset, we ranked 130 the significant cis genes using the Sobel test of mediation (Sobel 1982) to predict the driver gene of the 8 in UNIPROT (P-value = 0.0016), COSMIC (P-value = 0.0012) and the combined test (union of driver 141 databases) (P-value = 0.0041), and predicted Rank-1 driver genes in deletions were significantly enriched 142 for tumor suppressors in TUSON (P-value = 0.0045), UNIPROT (P-value = 0.016), COSMIC (P-value = 143 0.002), and the combined test (P-value = 0.013). Among the 65 Rank-1 cis genes ( Supplemental Table   144 S4), known cancer drivers included MCL1, ACTL6A, MYC, CCND1, FOXA1, ERBB2, CCNE1 145 (oncogenes in amplifications) and RPL5, ZMYND10, KMT2C, CSMD1, CDKN2B, PTEN, CREBL2,  
146
FANCA and ARHGAP35 (tumor suppressors in deletions) ( Supplemental Table S5 ).
iEDGE identifies amplification-driven gene dependencies in TCGA breast cancer
148
In addition to the prediction of known cancer drivers, we assessed whether iEDGE was capable of 149 identifying genes with copy-number driven cancer dependencies, specifically, amplification-driven gene 150 dependencies (see Methods). To this end, we identified genes with increased essentiality in an amplified 151 state using DepMap data of genetic screens (RNAi screens) paired with copy number data (CCLE) 152 ( Supplemental Table S6 ), and tested for their enrichment among iEDGE Rank-1 cis genes. In the TCGA 153 breast cancer dataset, we found a highly significant enrichment of Rank-1 cis genes among genes with 154 amplification-driven gene dependencies (Fisher test one-sided P-value = 3.53e-5). These were ERBB2, 155 CCNE1, CCND1, FOXA1, ANKRD17, MCL1. All of these genes are linked to breast cancer development 156 in the overexpressed state. ERBB2, CCND1, CCNE1 are well-characterized oncogenes present among our 9 In summary, using the cis gene mediation step, we identified known SCNA-associated breast cancer gene 164 drivers and novel genes with amplification-driven gene dependency that are of potential prognostic or 165 therapeutic value.
166
TCGA pan-cancer analysis 167 Next, the driver prediction procedure was carried out across 19 cancer types from TCGA (Supplemental 168   Table S7 ). We tested for the enrichment of Rank-1 cis genes with known cancer drivers across the 19 169 cancer types and found significant enrichment (FDR < 0.05) in 15 out of 19 cancer types (Kolmogorov-170 Smirnov test of p-values against uniform [0,1]: p-value = 2.5e-13) ( Supplemental Table S8 ).
171
Additionally, we tested for the enrichment of Rank-1 cis genes with genes manifesting amplification- Table S9 ).
175
To assess the importance of the cis mediating step for the identification of known cancer drivers, we 176 ordered Rank-1 cis genes ( Supplemental Table S10 ) by the number of cancer types they occur in, and 177 tracked which of these genes were validated cancer drivers. The derived ordered Rank-1 gene list was 178 then compared with the ordered list of recurrent top differentially expressed (D.E.) cis genes in each 179 SCNA, irrespective of their cis-mediating rank ( Supplemental Table S11 ), as well as with the ordered list 180 of all recurrent differentially expressed cis genes in each SCNA ( Supplemental Table S12 ). These 181 comparisons confirmed that the recurrent Rank-1 cis genes were more likely to capture known drivers 182 than both the recurrent top D.E. cis genes and all cis genes ( Figure 3A ). Remarkably, among the top 15 183 Rank-1 cis genes, 14 genes were known cancer drivers (PTEN, WWOX, CCNE1, CDKN2A, MAP2K4, 
194
In addition to enrichment for known cancer drivers, Rank-1 cis genes that frequently occur across cancer 195 types ( Supplemental Table S10 
203
Evaluation of reproducibility of Rank-1 cis genes
204
To evaluate the reproducibility of cis gene ranking based on mediation testing, we quantified the for calculation of WFTM) ( Figure 4B ). In particular, while Rank-1 cis genes with lower fraction of 213 inclusion across bootstrapped resamples tend to have lower WFTM, Rank-1 cis genes with higher 214 fractions of inclusion show more variability in WFTM but generally tend to have higher WFTM. The 215 fraction of inclusion is negatively associated with the entropy of WFTM of cis genes in SCNAs of interest 216 ( Figure 4C ). This is an indication that SCNAs with a single dominant cis gene mediating the majority of 217 trans genes (lower entropy) tend to yield more reproducible Rank-1 cis genes across bootstrapped 218 resamples than SCNAs with multiple cis genes with similar trans mediation (higher entropy). real datasets that were used to test and validate iEDGE. Specifically, high correlation between SCNA and 227 cis genes and between SCNA and trans genes is expected given that only cis and trans genes that were 228 significantly expressed with respect to the SCNA were considered prior to mediation testing.
229
Additionally, sufficient sample size is achieved in most of TCGA datasets tested ( Supplemental Table   230 S7), with the only exception being the TCGA Adrenocortical carcinoma dataset (n = 77) in which 231 mediation results should be interpreted with caution.
232
Graphical Portal of iEDGE Results Enable Targeted Queries
233
In order to enable fast interactive browsing of iEDGE precomputed runs on massive datasets such as the 234 TCGA pan-cancer set, we developed a web portal (https://montilab.bu.edu/iEDGE/) to allow users to 235 query iEDGE results selectively by cancer types, genes, and SCNAs. This portal displays graphical and 12 tabular results for each step of the iEDGE pipeline, including differential expression of cis and trans 237 genes, mediation analysis for driver prediction, and pathway enrichment analysis.
238
An overview of an example walkthrough of a targeted query is illustrated in Figure S2 . Here, the TCGA 239 breast cancer (BRCA) report is selected and the gene query is ERBB2 (HER2). The table of differential 240 expression results is available for the cytoband 17q12 in which ERBB2 resides in. Additionally, results of 241 the mediation testing and driver gene prediction is available in a bipartite graph format. In this case, the 242 graph indicates that ERBB2 is the top mediating cis gene and the predicted driver of the SCNA.
243
Discussion
244
Methods developed for the integrative analysis of (epi-)DNA regulators and gene expression data often 245 focus only on the genes harbored by the alteration regions, while not considering the downstream (trans-246 )effects, which may limit a method's ability to detect cancer driver genes. We present a computational 247 framework for the integrative analysis of (epi-)DNA and gene expression data for large-scale datasets, 248 iEDGE, that is able to thoroughly catalogue the cis and trans effects of epi-(DNA) alterations, and to 249 predict the most likely cis-driver genes based on the extent of their mediation of downstream trans-genes.
250
The first step of the iEDGE pipeline uses differential expression analysis to determine the cis and trans 251 genes that are associated with the presence/absence of a particular epi-DNA alteration across samples. By 252 measuring the alterations' association with trans genes we capture meaningful biological mechanisms 253 representing downstream effects that are generally missed by tools that only consider genes within the 254 alterations (e.g., GISTIC2.0). Trans genes are of potential high relevance considering that (epi-)DNA 255 regulators such as SCNAs harbor many upstream genes in signaling pathways, e.g., transcription factors, 256 wherein the set of target genes effected can shed light on processes or pathways associated with disease 257 progression.
258
The second step of the pipeline, the mediation analysis, ranks the set of cis genes by the extent of their 259 mediation of trans genes. We showed that mediation analysis captures important cancer driver genes in 13 our study of the TCGA breast cancer dataset. We then expanded these results by performing a pan-cancer 261 analysis across 19 cancer types in the TCGA, further highlighting our tool's ability to identify known, as 262 well as potentially novel drivers.
263
We conducted extensive in silico validation of predicted cis driver genes, by first testing for their 264 enrichment with known drivers from multiple cancer driver databases. We then characterized predicted 265 drivers by testing for their "essentiality" against genetic screens and cellular model data included in the 266 DepMap, to explore SCNA-associated gene dependencies. Both analyses showed that our list of predicted 
294
These approaches are similar to the mediation testing step of iEDGE, but they are more conservative 295 models that detect full mediation, e.g., significant hits are instances in which the conditional 296 independence given the mediator is zero, a condition that is rarely satisfied by genomic data, whereas 297 mediation tests are also able to capture partial mediation in which the association between the 298 independent and response variable is significantly reduced in size when the mediator is introduced but 299 may still be different from zero.
300
One assumption used in the iEDGE analysis presented in this study is that the number of trans genes that 301 a cis gene mediates is a proxy measure of a gene's importance (i.e., of its likelihood of being a cancer 302 driver). This is a simple and intuitive heuristic to estimate the extent of transcriptional impact from each 303 (epi-)DNA regulator, albeit it may not be an appropriate assumption for specific use cases. For more 304 targeted analysis, one may be only interested in predicting the cis gene that mediates gene targets in a 305 particular pathway. Our tool is customizable in that the user can specify the set of trans genes to consider 306 for mediation based on their membership in a pathway of interest or an experimentally derived gene 307 signature.
308
We use SCNA as an example of epi-DNA events to demonstrate a convenient use case for this tool as 
320
In the case of SCNAs, cis genes of each SCNA in this list are defined as genes within the focal peaks of 321 the SCNA, and trans genes are defined as genes outside of the focal peaks. Then, iEDGE performs 322 differential expression analysis to identify cis and trans genes significantly associated with each SCNA 323 and, optionally, pathway enrichment analysis of each significant cis and trans gene sets ( Figure 1A ).
324
Next, iEDGE predicts cis driver genes using mediation analysis, wherein each differentially expressed cis 325 gene is ranked by the number of differentially expressed trans genes it mediates as determined using the 326 Sobel test of mediation ( Figure 1B ).
327
Copy number and gene expression pre-processing
328
We utilized the dataset of somatic copy number alterations and RNA-seq from the TCGA breast cancer 329 cohort, which was preprocessed using Firehose v0.4.13 and downloaded from the Broad Institute TCGA 330 GDAC repository (http://gdac.broadinstitute.org/runs/).
331
The SCNA dataset was preprocessed using GISTIC2.0 under the Firehose run release 332 analyses__2015_08_21, which identified 29 significant focal amplifications and 40 significant focal 333 deletions to be considered for integrative analysis (Broad Institute TCGA Genome Data Analysis Center identified by GISTIC2.0 as genes in the wide peak of each significant SCNA with boundaries selected at 337 the confidence level of 0.99. Trans genes were identified as genes outside the wide peak of each SCNA.
338
The gene expression data is a RSEM processed gene expression matrix (stddata__2015_06_01). 
348
Determining significantly expressed SCNA associated cis and trans genes 349 We performed differential expression of cis and trans genes with respect to each GISTIC2.0 defined 350 significant focal SCNA peak. The significance of differential expression was estimated using limma 351 (Ritchie et al. 2015) for each SCNA with samples split into two groups (amplified vs. normal for 352 amplification peaks, and deleted vs. normal for deletion peaks) using FDR < 0.25 and fold change > 1.2 353 for cis genes, and FDR < 0.01 and fold change > 1.5 for trans genes. One-sided significant levels were 354 reported for cis genes with the rationale that a focal amplification is commonly associated with an 355 increase in gene expression and a deletion is associated with a decrease in gene expression. Two-sided 356 significant levels were reported for trans genes, as indirect downstream effects can occur through either 357 transcriptional repression or activation. 
Pathway enrichment analysis of significant cis and trans gene sets
364
For breast cancer-specific pathway enrichment results, pathways with significant enrichment (FDR < 365 0.25) in any SCNA were reported ( Figure 2 ). In addition, each SCNA was labeled according to its over-366 representation in a particular breast cancer subtype using a one-sided Fisher exact test comparing counts 367 of SCNA occurrence within vs. outside each breast cancer subtype (FDR < 0.05). Subtype-specific 368 SCNAs were subsequently used in conjunction with pathway enrichment results to determine subtype-369 specific pathway enrichments using a one-sided Fisher exact test (FDR < 0.05).
370
Mediation testing and prediction of cis drivers
371
To elucidate which cis genes are likely to mediate the association between copy number alteration and 372 trans gene expression, we used the Sobel test to estimate the mediation effect of each cis gene and its 373 significance (Sobel 1982) . Briefly, we model the association for each triplet of SCNA, cis gene, and trans 374 gene using the linear regression models specified in Figure 1B 
379
An important simplifying model assumption is that the association between each SCNA and trans gene is 380 mediated by at most one cis gene, therefore the cis gene mediator for each SCNA-trans gene pair is 381 chosen based on the most significant mediation effect (ranked by the FDR values of the mediation test).
Once the cis genes mediator is determined for each unique trans gene, the mediation effect of cis gene i 383 on trans gene j can be expressed as either binary (0 or 1), based on the significance of the mediation, or as (Table S7 ). Enrichment tests were conducted separately for each reference 401 database and driver type, i.e., oncogene ("_OG"), tumor suppressor ("_TN"), or both ("_COMBINED"), 402 as well as using the union of the driver genes across databases (column "ANY" indicates union of drivers 403 across knowledge bases dependency score corresponds to high gene dependency, e.g., an increased gene essentiality. In contrast, a 420 high gene dependency score corresponds to non-essential genes. We looked for genes with significantly 421 negative association between copy number and Gene Dependency Score, that is, genes in which higher 422 copy number is associated with higher gene essentiality, using a one-sided t-test on the coefficient α 423 (alternative hypothesis α < 0). Additionally, FDR correction was performed across p-values for all genes.
424
Since gene dependency scores are calculated from only gene knockdowns, we were only able to test 425 amplification-driven gene dependencies, whereas overexpression assays would be needed for detection of 426 deletion-driven gene dependencies.
427
Finally, to determine if iEDGE was able to uncover an enrichment of amplification-driven gene 428 dependencies, we tested for enrichment of genes with amplification-driven gene dependencies among 429 iEDGE-predicted Rank-1 cis genes using a one-sided Fisher test on the contingency table of counts (rows: 20 membership in Rank-1 vs. non-Rank-1, columns: presence vs. absence of amplification driven gene 431 dependencies).
Pan-Cancer Analysis
433
TCGA gene expression and copy number (GISTIC2.0) data were retrieved using Firehose v0.4.13 for 19 434 cancer types as summarized in Table S6 . 
443
We tested for enrichment of known cancer driver genes among Rank-1 cis genes in each of the 19 TCGA 444 cancer types using a one-sided Fisher test ( Supplemental Table S8 
452
We also tested for enrichment of amplification-driven gene dependencies in Rank-1 cis genes across the 
472
The Sobel test of mediation identifies cis genes that mediates SCNA and trans gene expression. To 473 determine the conditions in which mediation is correctly identified, we used a forward simulation 474 approach to generate labeled data of true positives and true negative, and then applied the mediation test 475 to estimate its sensitivity and specificity. Of note, for simplicity, these simulated instances represent total, 476 not partial, mediation.
477
True positive instances of mediation were generated using the following linear regression models:
Here, Xa denotes the independent variable (SCNA status), Za is a dependent variable (trans gene 481 expression) and Ya is a true mediator of Xa and Za (cis gene expression).
482
True negative instances, representing the lack of a mediation effect, were generated using the following 483 models:
Here, Xb is the independent variable (SCNA status) and Yb and Zb are both dependent variables generated 487 based on separate regression models from Xb.
488
Variables X, Y, Z are vectors of length n, representing the sample size of the data. X is a binary vector (0s 489 and 1s) corresponding to the binarized SCNA copy number status.  is the standard deviation of the 490 Gaussian noise term. We fixed 1 and 2 at 0.7 based on estimation from real data (TCGA breast cancer).
491
The mediation test was performed on 1000 simulated true positives and 1000 simulated true negatives, 
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